[SCHEDULE 13G/A] Evolent Health, Inc. Amended Passive Investment Disclosure
The Vanguard Group filed an Amendment No. 8 to a Schedule 13G/A for Evolent Health, Inc. (EVH), reporting that its beneficial ownership is now 0 shares (0%) due to an internal realignment. This realignment, effective January 12, 2026, means certain Vanguard subsidiaries will now report their holdings disaggregated from the main group. The filing clarifies that this is an administrative reporting change and not an indicator of trading activity by Vanguard.
Evolent announces appointment of Archie Mayani as chief product officer
Evolent Health, Inc. has announced the appointment of Archie Mayani as Chief Product Officer. Mayani brings over two decades of experience in healthcare technology and AI, having previously held leadership roles at GHX, Change Healthcare, UnitedHealth Group, and Amazon. Her expertise in value-based care, health tech, and AI transformation is expected to accelerate Evolent's product strategy and enhance its offerings for complex conditions.
EVH Stock Price, Quote & Chart | EVOLENT HEALTH INC - A (NYSE:EVH)
This article provides an overview of Evolent Health Inc. (EVH) stock, including its current price of $2.99, recent performance, and key financial metrics. The company reported Q4 earnings recently, beating EPS expectations but missing revenue, and analysts forecast a significant price increase for the stock over the next year. Both technical and fundamental analysis by ChartMill indicate challenges for EVH, with low ratings for both aspects.
Evolent Health (NYSE: EVH) CEO reports PSU grant and tax-withheld share dispositions
Evolent Health, Inc. CEO Seth Blackley reported significant equity award activity, including the grant of 1,425,310 performance-based share units (PSUs) and the acquisition of 58,921 Class A Common Stock shares from prior PSU settlements. To cover tax obligations, multiple dispositions of Class A Common Stock were made with specific share prices. Following these transactions, Blackley directly holds 836,962 Class A Common Stock shares and the newly granted PSUs, which are eligible to be earned based on future stock price and service conditions.
Precision Trading with Evolent Health Inc Class A (EVH) Risk Zones
The article discusses precision trading strategies for Evolent Health Inc Class A (EVH) based on AI-generated signals. It outlines institutional trading strategies including position, momentum breakout, and risk hedging, emphasizing risk management. The analysis provides support and resistance levels for various time horizons for EVH.
Evolent Health (EVH) president awarded PSUs and withholds shares for taxes
Evolent Health president Daniel McCarthy reported receiving 826,440 performance-based share units (PSUs) and acquiring 39,281 shares of Class A common stock from a prior PSU settlement. Concurrently, he had 24,027, 18,192, and 7,811 Class A shares withheld at prices between $3.25 and $3.58 to cover tax obligations. Following these transactions, McCarthy directly owns 423,022 Class A shares.
Evolent Health (NYSE: EVH) GC logs PSU grant and tax-share withholdings
Evolent Health's General Counsel, Jonathan Weinberg, reported receiving a grant of 179,661 performance-based share units and 4,910 shares of Class A Common Stock. The filing also detailed several tax-withholding dispositions where shares were withheld to cover tax obligations related to equity compensation. These transactions are tax-withholding dispositions, not open-market sales, and Weinberg now holds 244,512 shares of Class A Common Stock directly.
Evolent Health (EVH) CAO awarded PSUs while shares withheld for taxes
Evolent Health's Chief Accounting Officer, Shams Aammaad, was granted 55,173 performance-based share units (PSUs) and 1,686 shares of Class A Common Stock. Simultaneously, various amounts of Class A shares (4,311, 850, and 2,577) were withheld to cover tax obligations from the vesting and settlement of prior awards. The new PSUs are conditional on stock price performance from March 2027 to February 2029, with potential payouts ranging from 0% to 250% of the target level.
Evolent Health Shares Soar on Q4 Earnings and 2026 Revenue Guidance - News and Statistics
Evolent Health's shares surged by over 20% after the company exceeded fourth-quarter earnings expectations and provided a robust revenue forecast for 2026, targeting $2.4 billion to $2.6 billion. This optimistic outlook, suggesting approximately 30% growth, outweighed concerns about lower-than-expected adjusted EBITDA guidance. The stock's volatile performance and a recent gain fueled by hopes for interest rate cuts following a soft inflation report also contributed to market sentiment.
Evolent to Participate in Upcoming Investor Conferences
Evolent Health, Inc. announced its executive management team will participate in two upcoming investor conferences: the Cowen 46th Annual Healthcare Conference in Boston on March 3, 2026, and the Oppenheimer 36th Annual Healthcare MedTech and Services Conference virtually on March 17, 2026. Webcasts and replays of these events will be available on Evolent's investor relations website. The company specializes in improving health outcomes for people with complex conditions.
Evolent Health Q4 Loss Of US$3.84 Per Share Tests Bullish Margin Turnaround Narrative
Evolent Health (EVH) reported a Q4 loss of US$3.84 per share and a full-year 2025 net loss of US$579.4 million, challenging a bullish narrative of margin improvement. While revenue growth is around 15% annually, net losses have worsened faster at 21.2% per year over the last five years. The company's low P/S ratio of 0.2x and a DCF fair value of US$10.51 suggest a potential valuation gap for investors willing to look past its substantial losses.
Analysts Offer Insights on Healthcare Companies: Evolent Health (EVH) and Nanosonics Limited (OtherNNCSF)
Two healthcare companies, Evolent Health (EVH) and Nanosonics Limited (NNCSF), recently received bullish ratings from analysts. William Blair reiterated a Buy rating on Evolent Health with an $8.00 average price target, while Morgans maintained a Buy rating on Nanosonics Limited with an A$4.00 price target. These recommendations highlight positive sentiment in the Healthcare sector for these companies.
Evolent Health Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Over the last quarter, four analysts have provided varying ratings for Evolent Health (NYSE: EVH), ranging from bullish to bearish. The average 12-month price target for EVH is $8.5, indicating a 26.85% decrease from the previous average. Financial insights reveal Evolent Health has a market capitalization below industry averages, a negative revenue trend with a 22.83% decline, but strong net margin at -5.62%.
Evolent Health, Inc. SEC 10-K Report
Evolent Health, Inc. has released its annual 10-K report, detailing a significant decrease in total revenue to $1,876.2 million and a net loss of $579.4 million, largely due to a goodwill impairment charge. The company focuses on specialty care management and uses proprietary technology to deliver value-based care, despite operating in a complex regulatory environment and facing risks related to reliance on large partners and revenue unpredictability. Strategic initiatives include the sale of Evolent Care Partners and capital management to optimize its financial structure and pursue future growth.
EVH SEC Filings - Evolent Health Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Evolent Health (EVH) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It details recent financial activities, strategic transactions like the sale of its value-based primary care business, and governance changes, along with AI-powered summaries for quick understanding. The article also provides key financial data such as current stock price, market cap, and insider trading activities.
Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026
Evolent Health, Inc. (NYSE: EVH) announced it will release its 2025 fourth-quarter and year-end financial results on Tuesday, February 24, 2026, after market close, followed by a conference call at 5 p.m. ET. Shareholders and interested participants can access the live broadcast and an audio playback on Evolent's investor relations website. The company specializes in improving health outcomes for people with complex conditions, focusing on making healthcare simpler and more affordable.
Evolent Health to offer $140M in convertible notes, Targets 2025 debt, stock buyback
Evolent Health announced a private offering of $140 million in convertible senior notes due in 2029, with an option for initial purchasers to buy an additional $21 million. The company expects to use the net proceeds to repay its 2025 convertible notes and potentially repurchase shares of its Class A common stock. Additionally, Evolent Health plans to enter into capped call transactions to mitigate potential dilution from the conversion of the notes.
Take Care Before Diving Into The Deep End On Evolent Health, Inc. (NYSE:EVH)
Evolent Health, Inc. (NYSE:EVH) has a low price-to-sales (P/S) ratio of 0.2x, significantly below the Healthcare Services industry average. While analysts forecast comparable revenue growth for Evolent Health against the industry, its recent short-term revenue decline may be contributing to the low P/S ratio. Investors are advised to consider potential unobserved threats and revenue volatility despite the subdued risk of a price drop.
Price-Driven Insight from (EVH) for Rule-Based Strategy
This article from Stock Traders Daily provides a price-driven insight for Evolent Health Inc Class A (NYSE: EVH) using AI models. It outlines institutional trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The platform offers real-time entry and exit signals, risk-reward ratios, and custom risk management settings.
To recruit its new finance chief, Evolent puts $2.35M in stock on the table
Evolent (NYSE: EVH) announced a one-time inducement restricted stock unit award of 587,500 shares, valued at $2.35 million, to its new Chief Financial Officer, Mario Ramos. This award was granted under NYSE Listing Rule 303A.08 because Ramos was not a prior employee and will vest over three years, contingent on his continued employment. The market reacted positively, with EVH shares gaining 1.54% on the day this news was published.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. announced a one-time restricted stock unit award of 587,500 shares to Mr. Mario Ramos, their new Chief Financial Officer, effective January 2, 2026. This Inducement Award, valued at $2,350,000, is a material inducement for his employment and vests over three years, contingent on his continued employment. The award was granted in accordance with New York Stock Exchange Listing Rule 303A.08.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. announced a one-time inducement award of 587,500 restricted stock units to its new Chief Financial Officer, Mr. Mario Ramos, effective January 2, 2026. This award, valued at $2,350,000, vests over three years and was granted in accordance with NYSE Listing Rule 303A.08, as Mr. Ramos was a new hire. Evolent specializes in health outcomes for complex conditions.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08 – Company Announcement
Evolent Health, Inc. announced that its Compensation Committee approved a one-time restricted stock unit award for 587,500 shares to its new Chief Financial Officer, Mario Ramos. This inducement award, valued at $2,350,000, vests over three years and is contingent on his continued employment. The grant complies with NYSE Listing Rule 303A.08, as Mr. Ramos was not previously an Evolent employee.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. announced a one-time inducement award of 587,500 restricted stock units to its new Chief Financial Officer, Mr. Mario Ramos, effective January 2, 2026. This award, valued at $2,350,000, vests over three years, contingent on continued employment. The grant complies with NYSE Listing Rule 303A.08, as Mr. Ramos was not a previous employee.
Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08
Evolent Health, Inc. has granted a one-time restricted stock unit award covering 587,500 shares to its new Chief Financial Officer, Mr. Mario Ramos, effective January 2, 2026. This Inducement Award, valued at $2,350,000, was granted as a material inducement for his employment, adhering to NYSE Listing Rule 303A.08, and vests over three years contingent on continued employment.
Evolent Health (EVH) names new independent director and reiterates Q4 2025 guidance
Evolent Health announced that Cheryl Scott retired from its Board of Directors and Jill Smith was appointed as a new independent director. The company also reaffirmed its fourth-quarter 2025 revenue guidance of $462.0 million to $472.0 million and Adjusted EBITDA guidance of $30.0 million to $40.0 million. This guidance is consistent with its previous outlook from November 6, 2025.
Hopeful Week For Insiders Who Bought US$1.38m Of Evolent Health Stock
Evolent Health (NYSE:EVH) insiders recently bought $1.38 million worth of shares, though their investment is still down by $709k. Despite the losses, their purchases, including a significant one by Co-Founder Seth Blackley at a higher price, indicate a belief in the company's future. Insider ownership stands at 1.8%, valued at $8.1 million.
Evolent (NYSE: EVH) and AON unveil gold-card model removing most prior auth in oncology
Evolent Health (NYSE: EVH) and American Oncology Network (AON) have announced a national partnership to deploy a quality-focused cancer care model that aims to reduce costs, speed treatment, and eliminate prior authorization for providers who meet quality standards. Key elements include "gold-carding" providers, an AI analytics platform called MiBA for personalized treatment insights, and Evolent's Careology navigation program. The model, set to roll out in select markets in the year ahead, seeks to improve clinical decision-making and reward high-quality care.
UnitedHealth (UNH) Receives a Buy from Piper Sandler
Piper Sandler maintained a Buy rating on UnitedHealth (UNH) with a price target of $423.00, while Morgan Stanley also issued a Buy rating. However, TD Cowen maintained a Hold rating on the stock. Insider sentiment for UNH is currently negative, with some insiders selling shares recently.
Evolent Health Q3 2025 Earnings: Revenue Decline Expected - News and Statistics
Evolent Health (NYSE: EVH) is projected to report a 24.8% year-on-year revenue decline to $467.3 million for Q3 2025, with adjusted earnings around $0.11 per share. The company has previously missed revenue expectations, and its stock has dropped 20.6% in the last month, contrasting with some peers in the healthcare technology segment. The average analyst price target is significantly higher than its current share price.
Evolent Health, Inc. Appoints Mario Ramos as Chief Financial Officer, Effective January 1, 2026
Evolent Health, Inc. has announced the appointment of Mario Ramos as its new Chief Financial Officer, effective January 1, 2026. Mr. Ramos brings extensive experience from previous CFO roles at WellBe Senior Medical, Evolv Technology Holdings, Inc., and Edelman Financial Engines, as well as senior positions at CVS Health. His appointment is part of a broader restructuring of leadership roles within the company.
Evolent Announces Third Quarter 2025 Results
Evolent Health, Inc. announced strong financial results for the third quarter of 2025, exceeding expectations for Adjusted EBITDA and revenue. The company secured over $500 million in new annualized revenue set to launch in 2026, bringing its preliminary 2026 revenue forecast to $2.5 billion. Evolent also restructured its leadership team, appointing Mario Ramos as CFO and Katie DiPerna as COO, to support its accelerating growth and enhance financial discipline.
Precision Trading with Evolent Health Inc Class A (EVH) Risk Zones - news.stocktradersdaily.com
This article provides a detailed analysis of Evolent Health Inc (EVH) with a focus on AI-generated trading signals and risk zones. It highlights weak sentiment across all time horizons, suggesting a short bias, and presents specific trading strategies (Long, Breakout, Short) with entry points, targets, and stop losses. The analysis also includes multi-timeframe signal strength, support, and resistance levels.
Q3 2025 Results Nov. 6 — Evolent to Report Q3 financials, host 5 p.m. ET call and webcast of investor conferences
Evolent (NYSE: EVH) will release its third-quarter 2025 financial results on Thursday, November 6, 2025, after market close, followed by a conference call at 5:00 p.m. ET. The company will also participate in several upcoming investor conferences in November and December 2025. Live audio webcasts and replays of these events will be available on Evolent's investor relations website.
Evolent Health Sells Medicare Primary Care Business Serving 120K Members for $113M
Evolent Health (NYSE: EVH) has announced the sale of its value-based primary care business, Evolent Care Partners (ECP), to Privia Health Group for up to $113 million in cash. This strategic divestiture, involving operations serving over 120,000 members and 1,000+ physicians, aims to improve annual cash flow by over $7 million and focuses Evolent on its core specialty business. The company also reaffirmed its Q3 and full-year 2025 financial guidance, excluding the transaction's impact.
Cormedix (CRMD) Gets a Buy from Truist Financial
Truist Financial analyst Jailendra Singh has maintained a Buy rating on Cormedix (CRMD), with the company's shares closing recently at $13.70. Singh has an average return of -10.9% and a 35.82% success rate, specializing in the Healthcare sector. The analyst consensus for Cormedix is currently a Strong Buy, with an average price target of $19.33.
Why Evolent Health (EVH) Is Up 6.4% After Convertible Note Restructuring and Stock Repurchase
Evolent Health (EVH) saw a 6.4% stock increase following a US$166.75 million convertible note offering, which was used to repurchase existing notes and Class A common stock, enhancing financial flexibility. The company's investment narrative focuses on accelerating value-based care and scaling specialty platforms, with future growth dependent on converting client deals. Despite recent declines in revenue and profitability, the financial restructuring aims to support future growth targets, though execution risks and market volatility remain concerns.
Evolent Health prices convertible notes offering
This article states that Evolent Health has priced a convertible notes offering. No further details are available in the provided content.
Evolent prices $145 million convertible notes offering at 4.50%
Evolent Health, Inc. announced the pricing of $145 million in 4.50% convertible senior notes due 2031, an increase from the previously planned $140 million offering. The company plans to use the proceeds to repurchase existing 2025 convertible notes and Class A common stock. This financial maneuver is expected to reduce annual interest expenses.
Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock
Evolent Health, Inc. announced a proposed offering of $140.0 million in convertible senior notes due 2031. The company intends to use the proceeds to repurchase a portion of its existing 1.50% convertible senior notes due 2025 and approximately $40.0 million of its Class A common stock. This strategic financial move aims to manage existing debt and optimize its capital structure.
$140M Debt Offering: Evolent Health Launches Convertible Notes to Refinance Debt and Buy Back Stock
Evolent Health announced a proposed offering of $140.0 million in convertible senior notes due 2031, with an option for an additional $20.0 million. The company plans to use $100.0 million of the proceeds to repurchase existing 1.50% convertible senior notes due 2025 and $40.0 million to repurchase Class A common stock. This move is aimed at refinancing debt and returning capital to shareholders, extending debt maturities from 2025 to 2031.
Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors
Evolent Health, Inc. has nominated Shawn Guertin, former CFO of CVS Health, Aetna, and Coventry Health Care, to its Board of Directors. Guertin's nomination is part of Evolent's ongoing board refreshment efforts and aims to leverage his extensive experience in driving growth and profitability within the healthcare industry. He is expected to be elected at the annual stockholders meeting on June 5, 2025, taking the seat of the retiring Diane Holder.
Evolent Health, Inc. SEC 10-K Report
Evolent Health, Inc. has released its annual 10-K report, highlighting significant financial growth with a 30.1% increase in total revenue to $2,554.7 million, driven by expanding specialty care management services and strategic acquisitions. The company reported a net loss of $(93.5) million, an improvement from the previous year, and detailed its focus on value-based care, integrated technology, and strategic partnerships despite facing challenges like reliance on a limited number of partners and regulatory risks. Future plans include continued expansion through organic growth and acquisitions, while proactively managing medical costs and navigating a complex regulatory environment.
Evolent Announces Fourth Quarter and Full Year 2024 Results
Evolent Health, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024. The company reported revenue of $646.5 million for Q4 2024 and $2,554.7 million for the full year 2024, representing significant growth over the previous year. Evolent also secured contract amendments expected to yield a $115 million annual improvement for 2025 and maintained 100% partner contract retention across its top customers.
Evolent Health Explores Sale, Garners Inbound Interest From Private Equity Firms
Evolent Health Inc (NYSE: EVH) is reportedly exploring a sale after receiving takeover inquiries from private equity firms and healthcare providers, including TPG Inc, Clayton, Dubilier & Rice, and KKR & Co. Inc. Health insurer Elevance Health Inc (NYSE: ELV) has also shown interest and may partner with a private equity firm for a deal. Despite a 38% revenue increase in its latest quarter, the company faces financial challenges due to lower billing rates from payer customers.
Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan
Evolent Health, Inc. announced the pricing of $350.0 million in 3.50% convertible senior notes due 2029, with an option for initial purchasers to buy an additional $52.5 million. The company intends to use the net proceeds, along with available liquidity, to prepay a portion of its outstanding term loan facility. The notes are convertible into cash, Class A common stock, or a combination, at an initial conversion price of approximately $38.00 per share, representing a 42.50% premium over the closing price on December 5, 2023.
Form 424B7 Evolent Health, Inc.
Evolent Health, Inc. filed a Form 424B7 prospectus supplement for the resale of up to 8,474,576 shares of its Class A common stock by identified selling stockholders. The company will not receive any proceeds from these sales, which may occur through various methods including underwriters, brokers, or direct transactions. Investing in EVH Class A common stock involves risks, and the last reported closing price on November 2, 2023, was $24.01 per share.
Upmc Cuts Stake in Evolent Health (EVH)
Upmc has reduced its stake in Evolent Health (EVH), decreasing its ownership from 8.60% to 5.84%. Despite this, analyst forecasts predict a 38.90% upside for the stock, with projected annual revenue increasing by 39.17%. Institutional ownership of EVH has also seen a recent increase, with several large shareholders adjusting their positions.
EVOLENT HEALTH TO ACQUIRE IPG
Evolent Health announced its definitive agreement to acquire IPG, a surgical management solutions company for musculoskeletal conditions, for $375 million plus up to $87 million in contingent consideration. This acquisition aims to expand Evolent's value-based specialty care solutions, add new customers, and improve its financial profile by being immediately accretive to Adjusted EBITDA margins and cash flow. The transaction is expected to close in Q3 2022 and will diversify Evolent's customer and revenue mix.
Evolent Health stock spikes following report of potential sale to Walgreens
Evolent Health's stock saw a spike following a report suggesting a potential sale to Walgreens. This news comes less than two months after Evolent Health itself acquired another company. The article notes Evolent Health went public in 2015.
